FORA Capital LLC Purchases 2,877 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

FORA Capital LLC raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 229.8% in the third quarter, Holdings Channel reports. The firm owned 4,129 shares of the company’s stock after acquiring an additional 2,877 shares during the quarter. FORA Capital LLC’s holdings in IDEXX Laboratories were worth $2,086,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of IDXX. International Assets Investment Management LLC lifted its holdings in shares of IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Clearbridge Investments LLC lifted its stake in IDEXX Laboratories by 696.0% during the 2nd quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock valued at $171,891,000 after acquiring an additional 308,493 shares during the period. Vontobel Holding Ltd. lifted its stake in IDEXX Laboratories by 3,325.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock valued at $111,229,000 after acquiring an additional 213,731 shares during the period. American Century Companies Inc. boosted its holdings in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after acquiring an additional 177,226 shares during the last quarter. Finally, 1832 Asset Management L.P. grew its stake in shares of IDEXX Laboratories by 4,193.1% in the second quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company’s stock worth $62,601,000 after acquiring an additional 125,498 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $421.76 on Thursday. The stock has a 50-day simple moving average of $455.52 and a two-hundred day simple moving average of $479.07. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The firm has a market capitalization of $34.54 billion, a PE ratio of 40.67, a P/E/G ratio of 3.74 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same period in the prior year, the firm posted $2.53 EPS. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of research analyst reports. Piper Sandler restated a “neutral” rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Barclays dropped their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Finally, JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.